Regulatory Framework for Fixed Dose Combination Drugs in India – Prelims Specific

Fixed Dose Combination drugs combine multiple active ingredients in one dose. While beneficial for chronic disease compliance, irrational combinations pose public health risks and drive antimicrobial resistance. Regulated under the Drugs and Cosmetics Act of 1940, these drugs fall under the oversight of the Central Drugs Standard Control Organisation. Understanding the division of power between state licensing authorities and the central government is crucial for aspirants to avoid common exam traps regarding drug approval authority.

Introduction
Why in News?
Static Link
Institutional Link
Core Prelims Facts
Important Terms and Concepts
Bodies / Organisations / Institutions
Schemes / Laws / Reports / Conventions
Possible UPSC Prelims Traps
One-Minute Revision Notes
Practice MCQ for Prelims

Introduction

Fixed Dose Combination (FDC) drugs involve combining two or more active pharmaceutical ingredients into a single unit. While they simplify treatment, the rise of irrational combinations—those lacking therapeutic justification—threatens public health. This issue is significant for UPSC as it bridges public health governance, constitutional obligations under Article 21, and the functioning of statutory regulatory bodies.

Why in News?

Recent regulatory focus has intensified on delisting and banning irrational FDC drugs from the Indian market. The discourse highlights the need for stringent clinical trial data and improved post-marketing surveillance to ensure only safe, evidence-based combinations remain in circulation.

Static Link

The regulation of drugs in India is governed by the Drugs and Cosmetics Act, 1940. This legislation serves as the primary tool for the government to oversee the import, manufacture, distribution, and sale of pharmaceutical products. From a Prelims perspective, UPSC often tests the mandate of regulatory bodies and their ability to enforce national standards across state boundaries.

Institutional Link

Central Drugs Standard Control Organisation (CDSCO): The apex regulatory body under the Ministry of Health and Family Welfare. It is responsible for the approval of new drugs, conduct of clinical trials, and setting standards.
Drugs Controller General of India (DCGI): Heads the CDSCO and acts as the licensing authority for drugs of national importance.
Drug Technical Advisory Board (DTAB): A statutory body under the Drugs and Cosmetics Act that advises the Central and State governments on technical matters arising out of the administration of the Act.

Core Prelims Facts

FDCs were originally designed to improve patient compliance in chronic disease management.
Irrational FDCs are those that lack therapeutic superiority or safety evidence.
Excessive use of irrational antibiotic combinations is a primary driver of Antimicrobial Resistance (AMR) in India.
Regulatory responsibility is shared, but the CDSCO provides central oversight for safety and efficacy standards.

Important Terms and Concepts

Fixed Dose Combination (FDC): A pharmaceutical product containing two or more active ingredients in a fixed ratio of doses.
Antimicrobial Resistance (AMR): The ability of microorganisms to resist the effects of drugs that once successfully treated them.
Pharmacovigilance: The practice of monitoring the effects of medical drugs after they have been licensed for use, especially to identify and evaluate previously unreported adverse reactions.

Bodies / Organisations / Institutions

Ministry of Health and Family Welfare: The parent ministry responsible for drug regulation and public health policy.
CDSCO: An executive agency that serves as the national regulatory authority.

Schemes / Laws / Reports / Conventions

Drugs and Cosmetics Act, 1940: The foundational law governing the manufacture, sale, and distribution of drugs in India.

Possible UPSC Prelims Traps

Trap: Assuming the CDSCO has exclusive power over all drug licensing. In reality, licensing is often a shared function, with State Licensing Authorities (SLAs) frequently granting licenses that the CDSCO later finds to be irrational or unapproved.
Trap: Confusing the Ministry of Health and Family Welfare (regulator) with the Ministry of Chemicals and Fertilizers (which oversees the pharmaceutical industry as an economic sector).
Trap: Treating the "ban" on a drug as an automatic, nationwide event; in practice, enforcement at the retail level often requires state-level synchronization with central notifications.

One-Minute Revision Notes

Primary Legislation: Drugs and Cosmetics Act, 1940.
Apex Regulatory Body: CDSCO.
Nodal Ministry: Ministry of Health and Family Welfare.
Key Health Risk: Irrational combinations exacerbate Antimicrobial Resistance (AMR).
Regulatory Challenge: Fragmentation between Central and State licensing authorities.

Practice MCQ for Prelims

1. With reference to the regulation of drugs in India, consider the following statements:

1. The Central Drugs Standard Control Organisation (CDSCO) is the only body authorised to grant manufacturing licenses for all drugs in India.

2. The Drugs and Cosmetics Act, 1940, mandates that all Fixed Dose Combinations must undergo mandatory clinical trials before receiving market approval.

Which of the statements given above is/are correct?

A) 1 only

B) 2 only

C) Both 1 and 2

D) Neither 1 nor 2

Answer: B

Explanation: Statement 1 is incorrect because State Licensing Authorities (SLAs) also grant manufacturing licenses, leading to the regulatory fragmentation where irrational drugs sometimes enter the market. Statement 2 is correct as the legal framework requires safety and efficacy data, including clinical trials, for drug combinations.